Parkinson’s Drug Treatments Will Reach $3471m In 2020 New Study Predicts

06 September 2018
Pharma

A new report by visiongain forecasts worldwide sales of drugs to treat Parkinson’s disease will reach $3471 million in 2020. That revenue prediction and others appear in Parkinson’s Disease: World Drug Industry and Market 2016-2026, published in May 2016. Visiongain is a business information company based in London, UK.

Visiongain forecasts the overall market for Parkinson’s disease (PD) therapies will grow steadily to 2026. Rising disease prevalence, due to ageing populations will stimulate the market. Advances in technology and development of new drug targeting will further augment the drug market for the treatment of Parkinson’s disease. The research and development (R&D) pipeline holds promise too, especially for disease-modifying agents.

Current treatment options offer symptomatic relief, with dopamine-regulating drugs dominating the market. Visiongain forecasts the emphasis on dopamine will gradually shift to the emergence of two new drug classes, which show potential of addressing neuroprotective and disease modifying paradigms. At the moment Deep Brain Stimulation (DBS), a medical device, offers effective symptom relief and long term treatment. DBS has been shown to help alleviate some of the most common and debilitating symptoms of Parkinson’s disease such as tremor, rigidity, stiffness, slowed movement, walking problems and some of the negative symptoms of other PD therapeutics, such as levodopa. In the next decade, stem cell therapies, such as those which are being developed by the International Stem Cell Corporation (ISCO) offer disease modifying potential. This has major implications on the industry as it may provide the cure millions of Parkinson’s disease patients around the world are hoping for.

Arvind Deol, a pharmaceutical & medical device analyst in visiongain, said:

“The Parkinson’s disease market holds much potential. An increase in prevalence and an unprecedented elder population provides the market room to grow and a consistent consumer base. The advent of generic alternatives has brought with it the final years of the current generation of blockbuster Parkinson’s disease medications, as a reduction in healthcare spending in key markets continues to drive generic growth.

Ultimately, the current generation of Parkinson’s disease pharmaceuticals, designed to help relieve symptoms, is coming to an end. Within the next decade, the advent of disease modifying therapies will reshape the Parkinson’s disease industry. Overall the Parkinson’s disease market is expected to grow with a CAGR of 1% from 2015-2026.”

Visiongain’s new report finds the Parkinson’s treatment market will change by 2026, with new mechanisms of drug action capturing sales. Also biomarkers will help validate trials of neuroprotective agents and prove disease modification.

That study shows revenue forecasts to 2026 at overall world market, submarket, product and national level. It forecasts world sales for the following segments:

• Dopaminergic agents
• Dopamine receptor agonists
• COMT inhibitors
• MAO inhibitors
• Treatments with other modes of action (grouped).

That investigation also analyses leading companies there, including GSK, Novartis, Orion Pharmaceuticals, Boehringer Ingelheim and Teva Pharmaceutical Industries.

The analysis discusses R&D and commercial progress, shows research interviews and predicts PD drug revenues to 2026 in leading national markets. That work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC nations).

Parkinson’s Disease: World Drug Industry and Market 2016-2026 adds to visiongain’s portfolio of reports on healthcare industries. Together those studies assess commercial potentials of pharmaceuticals, diagnostics and medical devices.

Recent News

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever